IMMUNE CHECKPOINT INHIBITOR THERAPY AND AUTOIMMUNE MANIFESTATIONS. A SINGLE BRAZILIAN CENTER EXPERIENCE.
- Morton A. Scheinberg, Brazil
Abstract
Background and Aims
Immune Checkpoint Inhibitor Therapy and Autoimmune Manifestations. A single Brazilian center experience.Rafael A. Schmerling, Antonio c. Buzaid, Carolina k. Haddad, Fabio AB Schutz, Fabio r. Kater, Juliana Pimenta, Fernando Maluf, William N, Camila Lopes, Dafne Bromberg, Ana C. Oliveira, Morton Scheinberg. Oncology Center and Autoimmune Disease Nucleus Hospital Beneficiencia Portuguesa São Paulo Brazil 01323-030, Evaluate the prevalence and type of autoimmune events in patients receiving checkpoint inhibitor (ICIs).
Methods
A single center retrospective study was performed in cancer patients receiving ICIs on the period of 2012-2019.
Results
Five hundred and forty four patients received ICIs during this period.The mean age was 63.8 years 62% were male and the remainder female. The mean time of appearance was 5.5 months. Organ, autoimmune manifestation present were in the endocrine, skin, pulmonary,musculoskeletal, gastrointestinal and the nervous system, in a total of 123 patients.Twenty one had preexisting autoimmune disease and required treatment with steroids,hormone replacement and six also needed immunobiological.Toxicity classification was seen in grade 1(37.5%) grade 2 (43%) and grade 3 or 4(19.5%).Thirty three patients discontinued due to toxicity or lack of response.It was also possible to identify a positive correlation between tumor regression and the appearance of autoimmune signs and symptoms.Melanoma accounted for 34% of the patient population receiving ICIs during this period and autoimmunity was detected in 60% of the patients.
Conclusions
This is one of the largest single center experience in Latin America confirming the association of autoimmune diseases with ICIs therapy in cancer patients.Discontinuation of ICIs due to autoimmunity was a rare event.